News &amp; Updates

Body surface area-based dosing of intravenous (IV) golimumab appears safe and provides pharmacokinetic exposure in paediatric patients with active polyarticular-course juvenile idiopathic arthritis similar to that found in adults with rheumatoid arthritis, according to the results of an open-label study.

IV golimumab works in kids with polyarticular-course juvenile idiopathic arthritis

Ivermectin useful for treating mild COVID-19

A 5-day course of the Food and Drug Administration-approved antiparasitic agent ivermectin appears safe and effective in the treatment of adult patients with early-onset mild COVID-19, a study has reported.

Ivermectin useful for treating mild COVID-19

Early tocilizumab treatment in ICU tied to lower COVID-19 mortality

10 Feb 2021 by

Critically ill patients who received tocilizumab within 2 days of admission to the intensive care unit (ICU) for COVID-19 had a lower risk of mortality than those not treated with tocilizumab, according to a recent study.

Early tocilizumab treatment in ICU tied to lower COVID-19 mortality

Major drug–drug Interactions occur in hospitalized solid tumour cancer patients

A clinical pharmacy service that provides relevant pharmacotherapy consultations may be beneficial to hospitalized solid tumour cancer patients to prevent potentially serious concerns caused by moderate or major drug–drug interactions, suggests a recent study.

Major drug–drug Interactions occur in hospitalized solid tumour cancer patients

Broad-spectrum antibiotic effective against chronic endometriosis

A two-week course of broad-spectrum oral antibiotic therapy helps resolve chronic endometritis in about 90 percent of cases, although it is unclear whether this beneficial effect translates to improved pregnancy outcomes, according to a study.

Broad-spectrum antibiotic effective against chronic endometriosis

Ruxolitinib improves outcomes in chronic graft-vs-host disease

09 Feb 2021 by

The oral Janus kinase (JAK) 1/2 inhibitor ruxolitinib may improve outcomes in patients with steroid-refractory or steroid-dependent chronic graft-vs-host disease (GVHD) compared with current best available therapy (BAT), according to results of the phase III REACH3 study presented at ASH 2020.

Ruxolitinib improves outcomes in chronic graft-vs-host disease

$Good glycaemic control, metformin use reduce fracture risk in diabetic patients$

Good glycaemic control, metformin use reduce fracture risk in diabetic patients

The risk of fracture is lower among patients with good glycaemic control on current metformin monotherapy than those who are untreated, reports a study. However, glycaemic control in patients receiving treatment other than metformin shows no association with fracture risk.

Good glycaemic control, metformin use reduce fracture risk in diabetic patients

Corticosteroids plus IVIg may lower death risk in patients with SJS/TEN overlap

Treatment with corticosteroids in combination with intravenous immunoglobulin (IVIg) is associated with a reduction in mortality risk among patients with Stevens-Johnson syndrome (SLS) and toxic epidermal necrolysis (TEN) overlap and TEN, a recent study has shown.

Corticosteroids plus IVIg may lower death risk in patients with SJS/TEN overlap